You are in : Home » Results & submissions » Select UOA » 15 - General Engineering » View submission: University of Edinburgh (joint submission with Heriot-Watt University) » Outputs » Detail

Output details

15 - General Engineering

University of Edinburgh (joint submission with Heriot-Watt University)

Return to search Previous output Next output

Output 42 of 305 in the submission

Article title

ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood

Type

D - Journal article

DOI

10.1063/1.4731647

Title of journal

Biomicrofluidics

Article number

024133

Volume number

Issue number

First page of article

ISSN of journal

1932-1058

Year of publication

2012

URL

http://bmf.aip.org/resource/1/biomgb/v6/i2/p024133_s1

Number of additional authors

Additional information

This represents the first commercial development of dielectrophoresis, with initial application of identifying the number and type of metastatic cancer cells in a patient’s blood. Current clinical techniques for doing this are limited to extracting cancer cells that express specific antibodies or are much larger than normal circulating blood cells. Dielectrophoresis overcomes these limitations because it is non-invasive, requiring no fluorescent labels or other molecular tags. Prototypes have been delivered by ApoCell Inc (CEO: Darren Davis, email available) to the US National Cancer Institute. Pethig acts as technical consultant for ApoCell Inc and ApoCell Europe GmbH (Leipzig).

Interdisciplinary

Yes

Cross-referral requested

Research group

A - Manufacturing & Materials

Proposed double-weighted

Double-weighted statement

Reserve for a double-weighted output

Non-English

English abstract